Despite major therapeutic advances, breast cancer remains prone to recurrence, particularly in patients with early-stage ...

According to the World Health Organization, cancer diagnoses remain a leading cause of death. However, scientific and medical communities have improved clinical outcomes for many people, transforming ...

This work was supported by the National Natural Science Foundation of China (Grant No. 82373113, XJ), Shenyang Breast Cancer ...

We hypothesized that circulating tumor DNA (ctDNA) molecular residual disease (MRD) analysis without prior mutational knowledge could be performed after neoadjuvant chemotherapy to assess ...

OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of expertise in ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

Marija Balic, MD, discusses challenges that remain to the widespread implementation of MRD-guided patient management in TNBC.

MRD detection is the future — allowing us to monitor patients in real-time. The data is strong and we're excited that our approach can now be incorporated into future studies." Dr. Roy Herbst, study's ...

Marija Balic, MD, discusses how circulating tumor DNA assays for molecular residual disease detection have evolved in recent ...